State Street’s Anixa Biosciences ANIX Stock Holding History

State Street’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$410K	Hold	159,040	–	–	﹤0.01%	3709
2025 Q4	$496K	Buy	159,040 +38,540	+32%	+$158K	﹤0.01%	3681
2025 Q3	$398K	Hold	120,500	–	–	﹤0.01%	3713
2025 Q2	$398K	Hold	120,500	–	–	﹤0.01%	3665
2025 Q1	$345K	Hold	120,500	–	–	﹤0.01%	3689
2024 Q4	$280K	Buy	120,500 +8,600	+8%	+$26.7K	﹤0.01%	3774
2024 Q3	$352K	Hold	111,900	–	–	﹤0.01%	3665
2024 Q2	$247K	Buy	111,900 +3,400	+3%	+$9.64K	﹤0.01%	3759
2024 Q1	$339K	Hold	108,500	–	–	﹤0.01%	3746
2023 Q4	$421K	Buy	108,500 +6,400	+6%	+$21.6K	﹤0.01%	3685
2023 Q3	$334K	Hold	102,100	–	–	﹤0.01%	3778
2023 Q2	$327K	Hold	102,100	–	–	﹤0.01%	3838
2023 Q1	$439K	Hold	102,100	–	–	﹤0.01%	3786
2022 Q4	$434K	Hold	102,100	–	–	﹤0.01%	3818
2022 Q3	$502K	Hold	102,100	–	–	﹤0.01%	3776
2022 Q2	$312K	Hold	102,100	–	–	﹤0.01%	4013
2022 Q1	$280K	Buy	102,100 +11,213	+12%	+$32.9K	﹤0.01%	4263
2021 Q4	$270K	Hold	90,887	–	–	﹤0.01%	4218
2021 Q3	$434K	Buy	90,887 +67,600	+290%	+$305K	﹤0.01%	4033
2021 Q2	$90K	Buy	+23,287	New	+$99.2K	﹤0.01%	4379

Other funds holding ANIX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street's ANIX Position: Q1 2026 in Review

State Street held its Anixa Biosciences (ANIX) position steady in Q1 2026 at 159,040 shares worth $410K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

State Street first reported a position in ANIX in Q2 2021 and has held it in 20 quarters since. The position peaked at $502K in Q3 2022. 60 funds tracked by Wall St. Rank hold ANIX as of Q1 2026.

State Street held 159,040 shares of Anixa Biosciences worth $410K as of Q1 2026.
State Street left its Anixa Biosciences share count unchanged in Q1 2026.
Anixa Biosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3709 holding.
State Street first reported a position in Anixa Biosciences in Q2 2021 and has held it in 20 quarters since.
State Street's Anixa Biosciences position peaked at $502K in Q3 2022.
60 funds tracked by Wall St. Rank held Anixa Biosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.